This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Neer RM et al. (2001) Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344: 1434–1441
Compston J (2005) Recombinant parathyroid hormone in the management of osteoporosis. Calcif Tissue Int 77: 65–71
Black DM et al. (2003) The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 349: 1207–1215
Acknowledgements
The synopsis was written by Helen Jaques, Editorial Assistant, Nature Clinical Practice.
Author information
Authors and Affiliations
Ethics declarations
Competing interests
Paid advisory roles for the following:
Crescent diagnostics (Advisory Board)
Novartis (DSMB)
Amgen (DMC)
Servier (Advisory Boards, speaking engagements)
Procter & Gamble and Sanofi Aventis (Advisory Boards, speaking engagements)
Shire Pharmaceuticals (Advisory Board)
Nycomed (Advisory Board. speaking engagements)
Eli Lilly (speaking engagements)
Research grants from the following:
Procter & Gamble: RCT of risedronate in adults with cystic fibrosis
Servier: Study of bone histomorphometry in postmenopausal women receiving alendronate or strontium ranelate
Rights and permissions
About this article
Cite this article
Compston, J. Does parathyroid hormone treatment affect fracture risk or bone mineral density in patients with osteoporosis?. Nat Rev Rheumatol 3, 324–325 (2007). https://doi.org/10.1038/ncprheum0501
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ncprheum0501